269 related articles for article (PubMed ID: 16865780)
41. Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
Lu CH; Hung YJ; Hsieh PS
Eur J Pharmacol; 2016 Oct; 789():60-67. PubMed ID: 27397427
[TBL] [Abstract][Full Text] [Related]
42. Thiazolidinediones and the liver in humans.
Yki-Järvinen H
Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
[TBL] [Abstract][Full Text] [Related]
43. Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-α and SREBP-1c.
Zhang J; Tan Y; Yao F; Zhang Q
Mol Med Rep; 2012 Oct; 6(4):815-20. PubMed ID: 22858825
[TBL] [Abstract][Full Text] [Related]
44. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Ali MH; Messiha BA; Abdel-Latif HA
Pharm Biol; 2016 Jul; 54(7):1198-208. PubMed ID: 26134756
[TBL] [Abstract][Full Text] [Related]
45. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.
Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K
J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.
Park H; Shima T; Yamaguchi K; Mitsuyoshi H; Minami M; Yasui K; Itoh Y; Yoshikawa T; Fukui M; Hasegawa G; Nakamura N; Ohta M; Obayashi H; Okanoue T
J Gastroenterol; 2011 Jan; 46(1):101-7. PubMed ID: 20658156
[TBL] [Abstract][Full Text] [Related]
47. Lipoic Acid Prevents High-Fat Diet-Induced Hepatic Steatosis in Goto Kakizaki Rats by Reducing Oxidative Stress Through Nrf2 Activation.
Sena CM; Cipriano MA; Botelho MF; Seiça RM
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208622
[TBL] [Abstract][Full Text] [Related]
48. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat.
Raso GM; Esposito E; Iacono A; Pacilio M; Cuzzocrea S; Canani RB; Calignano A; Meli R
Eur J Pharmacol; 2009 Feb; 604(1-3):125-31. PubMed ID: 19135440
[TBL] [Abstract][Full Text] [Related]
49. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
[TBL] [Abstract][Full Text] [Related]
50. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
[TBL] [Abstract][Full Text] [Related]
51. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats.
Wei Y; Clark SE; Thyfault JP; Uptergrove GM; Li W; Whaley-Connell AT; Ferrario CM; Sowers JR; Ibdah JA
Am J Pathol; 2009 Apr; 174(4):1329-37. PubMed ID: 19246643
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Van Rooyen DM; Gan LT; Yeh MM; Haigh WG; Larter CZ; Ioannou G; Teoh NC; Farrell GC
J Hepatol; 2013 Jul; 59(1):144-52. PubMed ID: 23500152
[TBL] [Abstract][Full Text] [Related]
53. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
Oishi T; Terai S; Kuwashiro S; Fujisawa K; Matsumoto T; Nishina H; Sakaida I
Biochem Biophys Res Commun; 2012 May; 422(1):22-7. PubMed ID: 22554516
[TBL] [Abstract][Full Text] [Related]
54. Effect of atorvastatin and ezetimibe treatment on serum lipid profile and oxidative state in rats fed with a high-cholesterol diet.
Yasim A; Ozbag D; Kilinc M; Ciralik H; Toru H; Gümüşalan Y
Am J Med Sci; 2010 May; 339(5):448-52. PubMed ID: 20224310
[TBL] [Abstract][Full Text] [Related]
55. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
56. [Effect of electroacupuncture stimulation of back-shu points on expression of TNF-alpha and lipid peroxidation reaction in the liver tissue in non-alcoholic fatty liver disease rats].
Zeng ZH; Zeng MH; Huang XK; Chen R; Yu H
Zhen Ci Yan Jiu; 2014 Aug; 39(4):288-92. PubMed ID: 25219124
[TBL] [Abstract][Full Text] [Related]
57. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Fujita K; Yoneda M; Wada K; Mawatari H; Takahashi H; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Saito S; Iwasaki T; Terauchi Y; Nakajima A
Dig Dis Sci; 2007 Dec; 52(12):3455-64. PubMed ID: 17410441
[TBL] [Abstract][Full Text] [Related]
58. The effect of ezetimibe on NAFLD.
Averna M
Atheroscler Suppl; 2015 Feb; 17():27-34. PubMed ID: 25659874
[TBL] [Abstract][Full Text] [Related]
59. Triterpenoid-rich fraction from Ilex hainanensis Merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats.
Cui WX; Yang J; Chen XQ; Mao Q; Wei XL; Wen XD; Wang Q
Am J Chin Med; 2013; 41(3):487-502. PubMed ID: 23711137
[TBL] [Abstract][Full Text] [Related]
60. [An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis].
Zhao CY; Wang YD; Zhou JY; Jia B; Cui JF
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):450-5. PubMed ID: 17594812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
